Telbivudine for the management of chronic hepatitis B virus infection

Clinical Therapeutics

Volumn 29, Issue 12, 2007, Pages 2635-2653

  Matthews, S James ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

adverse events; hepatitis B; pharmacokinetics; telbivudine; therapeutic use

Indexed keywords

ADEFOVIR; CYCLOSPORIN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; HEADACHE; HEPATITIS B; HEPATOMEGALY; HUMAN; LACTIC ACIDOSIS; MALAISE; MEDLINE; MONOTHERAPY; MUSCLE WEAKNESS; MUTATION; MYALGIA; MYOPATHY; NAUSEA AND VOMITING; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; RHINOPHARYNGITIS; RISK ASSESSMENT; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; STEATOSIS; THROMBOCYTE COUNT; TIME SERIES ANALYSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS RESISTANCE;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DNA, VIRAL; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; MOLECULAR STRUCTURE; NUCLEOSIDES; PYRIMIDINONES; SALVAGE THERAPY;

EID: 38049046538     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.12.032     Document Type: Article

References (70)

1. Poland G., and Jacobson R. Clinical practice: Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 351 (2004) 2832-2838
2. Hepatitis B vaccines [World Health Organization (WHO) Web site]. Wkly Epidemiol Rec 79 (2004) 253-264 http://www.who.int/wer/2004/en/wer7928.pdf. Accessed December 4, 2007
3. Alter M., and Mast E. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 23 (1994) 437-455
4. Hoofnagle J., Doo E., Liang T., et al. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
5. Lok A., and McMahon B. Chronic hepatitis B: Update of recommendations. Hepatology 39 (2004) 857-861
6. Cooksley W., Piratvisuth T., Lee S., et al. Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
7. Marcellin P., Lau G., Bonino F., et al., for the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
8. Chan H., Leung N., Hui A., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 (2005) 240-250
9. Janssen H., van Zonneveld M., Senturk H., et al., for the HBV 99-01 Study Group and the Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 365 (2005) 123-129
10. Lau G., Piratvisuth T., Luo K., et al., for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
11. Lai C., Chien R., Leung N., et al., for the Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
12. Liaw Y., Leung N., Chang T., et al., for the Asia Hepatitis Lamivudine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
13. Leung N., Lai C., Chang T., et al., for the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
14. Gaia S., Marzano A., Smedile A., et al. Four years of treatment with lamivudine: Clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 20 (2004) 281-287
15. Delaney IV W. Progress in the treatment of chronic hepatitis B: Long-term experience with adefovir dipivoxil. J Antimicrob Chemother 59 (2007) 827-832
16. Red Book (2007), Thomson Healthcare Inc, Montvale, NJ
17. Pegasys (peginterferon alfa-2a) [prescribing information] (2007), Hoffman-LaRoche Inc, Nutley, NJ
18. Lai C., Dienstag J., Schiff E., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
19. Guan R., Lai C., Liaw Y., et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 16 Suppl 1 (2001) 44 Abstract A60
20. Moskovitz D., Osiowy C., Giles E., et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 12 (2005) 398-404
21. Lok A., Lai C., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
22. Thio C. Hepatitis B in the human immunodeficiency virus-infected patient: Epidemiology, natural history, and treatment. Semin Liver Dis 23 (2003) 125-136
23. Colonno R., Rose R., Bladick C., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
24. Colonno R., Rose R., Pokornowski K., et al. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 46 Suppl 1 (2007) S294 Abstract 781
25. Lok A., McMahon B., and for the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines Committee. Chronic hepatitis B: Update of recommendations. Hepatology 39 (2004) 857-861
26. Ide T., Kumashiro R., Kuwahara R., et al. Clinical course of patients with chronic hepatitis B with viral break-through during long-term lamivudine treatment. J Gastroenterol 40 (2005) 625-630
27. Tyzeka (telbivudine) tablets [prescribing information] (October 2006), Idenix Pharmaceuticals, Inc, Cambridge, Mass and East Hanover, NJ: Novartis Pharmaceuticals Corporation
28. Golitsina N., Danehy F., Fellows R., et al. Telbivudine phosphorylation by three enzymes: Implications for anti-hepatitis B virus activity in vitro and in the clinic. Hepatology 44 Suppl 1 (2006) 561A Abstract 1000
29. Hernandez-Santiago B., Placidi L., Cretton-Scott E., et al. Pharmacology of beta-L-thymidine and beta-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: Relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother 46 (2002) 1728-1733
30. Seifer M., Patty A., Dukhan D., et al. Telbivudine (LDT) preferentially inhibits second (+) strand HBV DNA synthesis. J Hepatol 42 Suppl 2 (2005) 151 Abstract 412
31. Bryant M., Bridges E., Placidi L., et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 45 (2001) 229-235
32. Delaney IV W., Yang H., Miller M., et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 48 (2004) 3702-3710
33. Stuyver L., Locarnini S., Lok A., et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33 (2001) 751-757
34. Yang H., Qi X., Sabogal A., et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10 (2005) 625-633
35. Bartholomeusz A., Yuen L., Locarnini S., et al. Understanding HBV resistance to telbivudine: Molecular modeling and database mining. J Hepatol 46 Suppl 1 (2007) S185 Abstract 486
36. Standring D., Patty A., Chapron C., et al. Resistance determination in patients experiencing virologic breakthrough following telbivudine or lamivudine therapy in the International GLOBE trial. Gastroenterology 132 Suppl 2 (2007) A-766 Abstract 1781
37. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Presented at: 57th Annual Meeting of the American Association for the Study of Liver Disease; October 27-31, 2006; Boston, Mass. http://www.natap.org/2006/AASLD/AASLD_18.htm. Accessed December 5, 2007.
38. Standring D., Seifer M., Patty A., et al. HBV resistance determination from the telbivudine GLOBE registration trial. J Hepatol 44 Suppl 2 (2006) S191 Abstract 514
39. Hu P., Jiang J., Wang H., et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 46 (2006) 999-1007
40. Zhou X., Marbury T., Alcorn H., et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother 50 (2006) 1721-1726
41. Zhou X., Lloyd D., Chao G., and Brown N. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 46 (2006) 275-281
42. Zhou X., Lim S., Lloyd D., et al. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B infection: Pharmacodynamic implications. Antimicrob Agents Chemother 50 (2006) 874-879
43. Borgia G., and Gentile I. Treating chronic hepatitis B: Today and tomorrow. Curr Med Chem 13 (2006) 2839-2855
44. Zhou X., Fielman B., Lloyd D., et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 50 (2006) 2309-2315
45. Lai C., Leung N., Teo E., et al., for the Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastro-enterology 129 (2005) 528-536
46. Zhou X., Fielman B., Dubuc-Patrick G., et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon alpha-2a or cyclosporine in healthy subjects. J Hepatol 44 Suppl 2 (2006) S194 Abstract 522
47. Zhou X., Pietropaolo K., Becker M., et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir. Gastroenterology 132 Suppl 2 (2007) A-766 Abstract S1782
48. Lai C., Lim S., Brown N., et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40 (2004) 719-726
49. Lai C., Leung N., Teo E., et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs. lamivudine vs. combination treatment in hepatitis B patients: Two-year results. Gastroenterology 128 Suppl 2 (2005) A-692 Abstract 320
50. Bzowej N., Lai C., Gane E., et al. Phase III comparison of telbivudine vs. lamivudine in patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year. Gastroenterology 130 Suppl 2 (2006) A765-A766 Abstract 482
51. Lai C., Gane E., Hsu C., et al. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology 44 Suppl 1 (2006) 222A Abstract 91
52. Thongsawat S., Lai C., Gane E., et al. Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study. J Hepatol. 44 Suppl 2 (2006) S49 Abstract 110
53. Poynard T., Chutaputti A., Hwang S., et al. Sustained off-treatment HBeAg response in telbivudine and lamivudine treated HBeAg-positive patients from the GLOBE study. J Hepatol. 46 Suppl 1 (2007) S27 Abstract 58
54. Jia J., Hou J., Yin Y., et al. Two-year results of a phase III comparative trial of telbivudine vs. lamivudine in Chinese patients. J Hepatol. 46 Suppl 1 (2007) S189 Abstract 497
55. Telbivudine versus lamivudine in adults with decompensated chronic hepatitis B and evidence of cirrhosis [ClinicalTrials.gov Web site]. http://www.clinicaltrials.gov/ct/show/NCT00076336?order=13. Accessed June 15, 2007
56. Zeuzem S., Lai C., Gane E., et al., for the GLOBE Study Group. Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients. Presented at: 41st Meeting of the European Association for the Study of Liver Diseases; April 26-30, 2006; Vienna, Austria (2007). http://www.natap.org/2006/EASL/EASL_26.htm Accessed December 5, 2007
57. DiBisceglie A., Lai C., Gane E., et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 44 Suppl 1 (2006) 230A-231A Abstract 112
58. Marcellin P., Chan H., Lai C., et al. In hepatitis B patients treated with either adefovir or telbivudine, maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy. J Hepatol. 46 Suppl 1 (2007) S193 Abstract 508
59. Heathcote E., Chan H.-Y., Lai C.-L., et al., for the 018 Study Group. A comparative trial of telbivudine and adefovir dipivoxil for treatment of HBeAg-positive, compensated chronic hepatitis B: 24 Week results. Presented at: Digestive Disease Week; May 20-25, 2006; Los Angeles, Calif. (2007). http://www.hivandhepatitis.com/2006icr/ddw/pdf/Heathcote.pdf Accessed December 5, 2007
60. Safadi R., Xie Q., Chen Y., et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: Results of the primary analysis at week 24. J Hepatol. 46 Suppl 1 (2007) S196-S197 Abstract 516
61. Bzowej N., Chan H., Lai C., et al. A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Final week 52 results. Hepatology. 44 Suppl 1 (2006) 563A Abstract 1005
62. Marcellin P., Chan H., Lai C., et al. 76 Week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine. J Hepatol 46 Suppl 1 (2007) S55 Abstract 124
63. Gane E., Lai C., Min A., et al. Adefovir salvage therapy for virologic break-through in telbivudine-treated patients from the GLOBE study. J Hepatol. 46 Suppl 1 (2007) S187-S188 Abstract 493
64. Study of combination therapy with LdT plus adefovir versus adefovir alone [ClinicalTrials.gov Web site]. http://www.clinicaltrials.gov/ct/show/NCT00376259?order=7. Accessed June 15, 2007
65. Trial of telbivudine combination therapy vs. continued adefovir monotherapy [ClinicalTrials.gov Web site].http://www.clinicaltrials.gov/ct/show/NCT00409019?order=5. Accessed June 15, 2007
66. Efficacy and safety of telbivudine in treatment naïve patients with HBeAg-positive chronic hepatitis B (CHB) [ClinicalTrials.gov Web site].http://www.clinicaltrials.gov/ct/show/NCT00412750?order=2. Accessed June 5, 2007
67. Telbivudine versus the combination of telbivudine and valtorcitabine in patients with chronic hepatitis B [ClinicalTrials.gov Web site].http://clinicaltrials.gov/ct/show/NCT00128544?order=1. Accessed June 5, 2007
68. An extension to viral kinetics study of telbivudine and entecavir in adults with chronic hepatitis B [ClinicalTrials.gov Web site].http://www.clinicaltrials.gov/ct/show/NCT00467545?order=1. Accessed June 7, 2007
69. Gerschenson M., and Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 4 (2004) 763-777
70. Wong J., and Pauker S. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. J Hepatol. 46 Suppl 1 (2007) S199 Abstract 522